TABLE 7.
Outcome | No of trials |
Number of events/total number |
Relative risk (95% Cl) |
I2 (%) |
||
---|---|---|---|---|---|---|
Magnesium | No magnesium | |||||
Death | 331,33,35 | 0/1917 | 1/1950 | 0.32(0.01–7.92) | 0.0 | |
Cardiac or respiratory arrest | 331,33,35 | 0/1917 | 0/1950 | Not estimable | NA | |
Pulmonary edema | 135 | 8/1096 | 3/1145 | 2.79(0.74–10.47) | NA | |
Respiratory depression | 231,35 | 41/1631 | 31/1672 | 1.31 (0.83–2.07) | 0.0 | |
Hypotension | 231,33 | 80/821 | 52/805 | 1.51 (1.09–2.09) | 3.6 | |
Tachycardia | 131 | 56/535 | 36/527 | 1.53(1.03–2.29) | NA | |
Severe postpartum hemorrhage | 231,33 | 28/821 | 26/805 | 1.06(0.63–1.79) | 0.0 | |
Cesarean section | 331,33,35 | 822/1917 | 834/1950 | 1.00(0.93–1.07) | 21.6 | |
Clinical and self-assessed maternal side effects of the infusion |
||||||
Flushing | 331,33,35 | 1119/1917 | 162/1950 | 7.56(3.39–16.88) | 93.8 | |
Nausea or vomiting |
331,33,35 | 312/1917 | 76/1950 | 4.60(1.54–13.75) | 91.5 | |
Sweating | 231,35 | 411/1631 | 57/1672 | 6.37(1.96–20.68) | 94.6 | |
Problems at injection site |
231,35 | 614/1631 | 68/1672 | 9.12(7.19–11.57) | 0.0 | |
Stopping of infusion because of adverse effects |
231,35 | 123/1631 | 44/1672 | 2.81 (2.01–3.93) | 0.0 | |
Any side effect | 331,33,35 | 1356/1917 | 343/1950 | 5.05(2.06–12.39) | 98.3 |
Cl, confidence interval; NA, not applicable